Exicure Reports No Revenue and Significant Losses in Q2 2026

Exicure, Inc. reported its financial results for the second quarter of 2026, revealing a continued lack of revenue and significant operating losses. The company recorded no revenue for the three and six months ended June 30, 2026, consistent with the same periods in 2025. Operating expenses for the second quarter were $1.05 million, a decrease of 58% from $2.51 million in the prior year, primarily due to reduced research and development costs and general administrative expenses. The net loss for the quarter was $1.12 million, a 57% improvement compared to a net loss of $2.62 million in the same quarter of 2025.

In terms of financial position, Exicure's cash and cash equivalents decreased to $1.72 million as of June 30, 2026, down from $3.75 million at the end of 2025. The company’s total assets also fell to $11.40 million from $14.04 million, while total liabilities increased slightly to $10.42 million from $10.12 million. The accumulated deficit grew to $207.16 million, reflecting ongoing operational challenges and the need for additional capital to sustain operations.

Strategically, Exicure has been focusing on evaluating various alternatives to maximize shareholder value, including potential acquisitions and partnerships. The company completed the acquisition of GPCR Therapeutics USA Inc. in January 2025, which has since been involved in clinical trials for blood cancer treatments. However, the company has faced challenges in meeting its financial obligations, including a milestone payment of $1 million due to GPCR, which is expected to be settled through the issuance of common stock due to cash constraints.

Operationally, Exicure has seen a significant reduction in its workforce, with full-time employees decreasing from eight to two over the past year. This reduction has contributed to lower general and administrative expenses, which were $2.18 million for the first half of 2026, down 42% from $3.73 million in the same period of 2025. The company is currently under scrutiny from Nasdaq for failing to meet minimum stockholder equity requirements, and it has submitted a plan to regain compliance.

Looking ahead, Exicure faces substantial uncertainty regarding its ability to continue as a going concern. The company has indicated that it will require additional financing to support ongoing operations and explore strategic alternatives. Management has acknowledged the challenges in raising capital, particularly given the current market conditions and the company's financial status. Without successful capital raising efforts, Exicure may face severe operational limitations or potential bankruptcy.